Novel Therapeutics Track

Invited applications are for projects in the pre-translational phase, where proof of concept has already been established, and implementation is possible within 1-2 years.

Eligibility and priority:

• Applications will be accepted from Active and Prolific Collaboration between Regular full-time TAU Researchers (NOT emeritus) and TASMC Researchers (M.D./Ph.D.)
• Invited applications are for projects in the pre-translational phase, where proof of concept has already been established (e.g. in vivo results) and implementation is possible within 2 years.

Criteria:

• Scope of unmet clinical need
• Novelty of approach
• Team suitability
• Quality of data
• Probability of Commercialization for Novel Therapeutics
• Feasibility (Budget and time)